跳至主要内容
临床试验/NCT02299557
NCT02299557已完成1 期

A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients

RDD Pharma Ltd1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2014年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
19
试验地点
1
主要终点
To examine the effect of Oxymetazoline gel on fecal incontinence episodes in the 8 hours following application.

研究概览

简要总结

This is an double blinded, cross-over study to determine the effect of Oxymetazoline gel on anal resting pressure and fecal incontinence in patients with spinal cord injury. Approximately 17 subjects are expected to complete this 10 weeks study that will include two treatment periods of 4 weeks each, and one 2 weeks wash out period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Signed written informed consent.
  • Male or female subjects 18 to 55 years of age;
  • Spinal Cord Injury that occurred at least 3 months from randomization day and less than 3 years from randomization day.
  • At least 4 unwanted/unexpected incontinent events/week

排除标准

  • Known allergy to Oxymetazoline or silicone.
  • Pregnancy or lactation.
  • Active cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities;
  • Type 1 diabetes mellitus;
  • Insulin treated type 2 diabetes mellitus;
  • Renal insufficiency.
  • Liver insufficiency.
  • Malignant disease within 5 years of screening;
  • History of rectal surgery.
  • History of HIV, hepatitis B, hepatitis C.
  • Has upon physical examination a rectal deformation or signs of rectal disease such as fissure, bleeding hemorrhoids, fistula, infection or space occupying lesion.
  • Has used, in the last 1 week, drugs that may affect blood coagulation, such as Aspirin (at a dose above 500 mg/day), Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine.
  • Hypertension (blood pressure over 150/105 mm Hg in screening visit)
  • Unable to understand the use instruction, as judged by the investigator.

研究组 & 干预措施

Treatment

Experimental

Intra-anal Oxymetazoline gel once daily

干预措施: Oxymetazoline gel (Drug)

Placebo

Placebo Comparator

Intra-anal Placebo gel once daily

干预措施: Placebo gel (Drug)

结局指标

主要结局

To examine the effect of Oxymetazoline gel on fecal incontinence episodes in the 8 hours following application.

时间窗: 4 weeks

次要结局

  • Number of participants with adverse events(4 weeks)
  • Pharmacokinetics (area under the curve [AUC]), peak concentration and half life time (T 1/2) of Oxymetazoline;(4 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验